SCHEMBL13087356

SCHEMBL13087356

COc1cccc(S(=O)(=O)N2CCC(Nc3cc(-c4cccc(C#N)c4)cc4ccncc34)CC2)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CCR6 P51684 8/20 0.46
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
BRD4 O60885 1/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
PKM P14618 1/20 0.40
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
DYRK1A Q13627 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GPR6 P46095 1/20 0.39
TP53 P04637 1/20 0.38
MAPT P10636 1/20 0.38
ROCK2 O75116 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13087153 0.90 CCR6 (0.51) CCR6BRD4CCNA2CDK2JAK2
SCHEMBL13087245 0.89 CCR6 (0.44) CCR6CYP11B1CYP11B2BRD4CCNA2
SCHEMBL13090008 0.88 CCR6 (0.51) CCR6CYP11B1CYP11B2BRD4CCNA2
SCHEMBL2424533 0.85 ROCK2 (0.43) CCR6BRD4CCNA2CDK2DYRK1A
SCHEMBL13087525 0.85 CCR6 (0.42) CCR6BRD4CCNA2CDK2JAK2
SCHEMBL13087712 0.85 ROCK2 (0.45) CCR6CYP11B1CYP11B2CCNA2CDK2
SCHEMBL13090006 0.84 NOS1 (0.49)
SCHEMBL13089969 0.84 ROCK2 (0.43) CCR6CYP11B1CYP11B2CCNA2CDK2
SCHEMBL13089944 0.83 CCR6 (0.42) CCR6CYP11B1CYP11B2BRD4CCNA2
SCHEMBL13087706 0.83 ROCK2 (0.42) CCR6BRD4CCNA2CDK2JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-8299055-B2 8-substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2012-10-30 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof ASAHI KASEI PHARMA CORPORATION (JP) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261701-A1 8-Substituted isoquinoline derivative and the use thereof RELA, NFKBIA, NFKB2 CCR6 3313/4885CYP11B1 353/4885CYP11B2 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.